prostaglandin biosynthesis Inhibitors
2 drugsAbout prostaglandin biosynthesis
Prostaglandin biosynthesis is the process by which prostaglandins are created, hormone-like lipid compounds mediating inflammation, pain, and fever. Inhibiting this process is a therapeutic strategy to alleviate these symptoms.
Prostaglandin biosynthesis is a target for pain management, evidenced by two FDA-approved drugs. Currently, there is no genetic evidence available linking prostaglandin biosynthesis directly to specific diseases.
Two small molecule drugs, ACULAR and ACUVAIL (both AbbVie), target prostaglandin biosynthesis. One drug is used in pain, and the other in an 'other' therapeutic area.
Top prostaglandin biosynthesis Drugs
AbbVie is the only company with approved drugs targeting prostaglandin biosynthesis.
High market concentration suggests potential entry barriers or partnering opportunities with AbbVie.
prostaglandin biosynthesis Drug Modality Landscape
Modalities
Routes of Administration
prostaglandin biosynthesis is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or biologics could create differentiation.
prostaglandin biosynthesis Clinical Trials 172 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on prostaglandin biosynthesis. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 8 | 5 | 2 | 62% |
| Phase 2 | 45 | 28 | 10 | 7 | 74% |
| Phase 3 | 32 | 19 | 3 | 9 | 86% |
| Phase 4 | 80 | 53 | 16 | 11 | 77% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
prostaglandin biosynthesis Drug Approval Timeline (1992 - 2009)
The first drug was approved in 1992 (ACULAR), and the most recent in 2009 (ACUVAIL).
The approval timeline suggests a potentially saturated market or declining interest in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 124 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on prostaglandin biosynthesis. A trial counts if an approved drug acting on prostaglandin biosynthesis is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.